DIVISION OF CORPORATION FINANCE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

Mail Stop 4546

October 24, 2016

Alexander A. Zukiwski Chief Executive Officer Arno Therapeutics, Inc. 200 Route 31 North, Suite 104 Flemington, NJ 08822

Re: Arno Therapeutics, Inc.

Registration Statement on Form S-1

Filed October 12, 2016 File No. 333-214074

Dear Mr. Zukiwski:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

You may contact Scot Foley at (202) 551-3383 or Mary Beth Breslin at (202) 551-3625 with any questions.

Sincerely,

/s/ Mary Beth Breslin for

Suzanne Hayes Assistant Director Office of Healthcare and Insurance

cc: Christopher J. Melsha, Esq. Fredrikson & Byron, P.A.